We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ACADIA Pharmaceuticals Extends Drug Discovery Collaboration with Allergan, Inc.
News

ACADIA Pharmaceuticals Extends Drug Discovery Collaboration with Allergan, Inc.

ACADIA Pharmaceuticals Extends Drug Discovery Collaboration with Allergan, Inc.
News

ACADIA Pharmaceuticals Extends Drug Discovery Collaboration with Allergan, Inc.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ACADIA Pharmaceuticals Extends Drug Discovery Collaboration with Allergan, Inc."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The research term of this collaboration has now been extended by the parties for an additional year through March 2013. ACADIA also has two other collaboration agreements with Allergan, which have led to clinical programs in the areas of chronic pain and glaucoma.

"We are pleased to extend our longstanding drug discovery collaboration with Allergan," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. "This productive alliance has continued to lead to interesting discoveries, which we hope to be able to translate into potential new therapies for glaucoma and related ophthalmic conditions."

During the extended term of the collaboration agreement, the parties will jointly pursue research in the area of ophthalmology. Allergan is entitled to exclusively license specified chemistry and related assets for development and commercialization. ACADIA will receive research funding and is eligible to receive license fees and milestone payments upon the successful achievement of agreed-upon clinical and regulatory objectives as well as royalties on future product sales, if any, worldwide.

Advertisement